- Home
- CNSP vs QUCY Comparison
CNSP vs QUCY Comparison
Compare CNSP & QUCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNSP | QUCY |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | Germany |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.9M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNSP | QUCY |
|---|---|---|
| Price | $4.96 | $3.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 2.1M | ★ 30.0M |
| Earning Date | 05-15-2026 | 06-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $74.34 |
| Revenue Next Year | N/A | $171.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.30 |
| 52 Week High | $10.59 | $3.97 |
Technical Indicators
Market Signals| Indicator | CNSP | QUCY |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 93.25 |
| Support Level | $2.01 | $0.39 |
| Resistance Level | $8.56 | N/A |
| Average True Range (ATR) | 0.97 | 0.46 |
| MACD | -0.00 | 0.30 |
| Stochastic Oscillator | 32.95 | 67.06 |
Price Performance
Historical ComparisonAbout CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
About QUCY Mainz Biomed N.V. Ordinary Shares
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.